NLRP3 and type 2 diabetes mellitus: Glyburide, a type 2 diabetes drug, was the first repositioned drug identified to inhibit the NLRP3 inflammasome by blocking ATP-sensitive K+ channels and reducing LPS-induced lethality in mice (29).